JP2017506904A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506904A5
JP2017506904A5 JP2016555603A JP2016555603A JP2017506904A5 JP 2017506904 A5 JP2017506904 A5 JP 2017506904A5 JP 2016555603 A JP2016555603 A JP 2016555603A JP 2016555603 A JP2016555603 A JP 2016555603A JP 2017506904 A5 JP2017506904 A5 JP 2017506904A5
Authority
JP
Japan
Prior art keywords
item
polypeptide
inhibitor
cells
pluripotent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555603A
Other languages
English (en)
Japanese (ja)
Other versions
JP6722108B2 (ja
JP2017506904A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/018801 external-priority patent/WO2015134652A1/en
Publication of JP2017506904A publication Critical patent/JP2017506904A/ja
Publication of JP2017506904A5 publication Critical patent/JP2017506904A5/ja
Application granted granted Critical
Publication of JP6722108B2 publication Critical patent/JP6722108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555603A 2014-03-04 2015-03-04 改善された再プログラム方法及び細胞培養基盤 Active JP6722108B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947979P 2014-03-04 2014-03-04
US61/947,979 2014-03-04
PCT/US2015/018801 WO2015134652A1 (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018028663A Division JP2018086018A (ja) 2014-03-04 2018-02-21 改善された再プログラム方法及び細胞培養基盤
JP2019148519A Division JP7170600B2 (ja) 2014-03-04 2019-08-13 改善された再プログラム方法及び細胞培養基盤

Publications (3)

Publication Number Publication Date
JP2017506904A JP2017506904A (ja) 2017-03-16
JP2017506904A5 true JP2017506904A5 (https=) 2018-04-05
JP6722108B2 JP6722108B2 (ja) 2020-07-15

Family

ID=54055848

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2016555603A Active JP6722108B2 (ja) 2014-03-04 2015-03-04 改善された再プログラム方法及び細胞培養基盤
JP2018028663A Pending JP2018086018A (ja) 2014-03-04 2018-02-21 改善された再プログラム方法及び細胞培養基盤
JP2019148519A Active JP7170600B2 (ja) 2014-03-04 2019-08-13 改善された再プログラム方法及び細胞培養基盤
JP2020151081A Pending JP2021000107A (ja) 2014-03-04 2020-09-09 改善された再プログラム方法及び細胞培養基盤
JP2022062448A Active JP7516452B2 (ja) 2014-03-04 2022-04-04 改善された再プログラム方法及び細胞培養基盤
JP2023118423A Active JP7738035B2 (ja) 2014-03-04 2023-07-20 改善された再プログラム方法及び細胞培養基盤
JP2025080312A Pending JP2025114793A (ja) 2014-03-04 2025-05-13 改善された再プログラム方法及び細胞培養基盤

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2018028663A Pending JP2018086018A (ja) 2014-03-04 2018-02-21 改善された再プログラム方法及び細胞培養基盤
JP2019148519A Active JP7170600B2 (ja) 2014-03-04 2019-08-13 改善された再プログラム方法及び細胞培養基盤
JP2020151081A Pending JP2021000107A (ja) 2014-03-04 2020-09-09 改善された再プログラム方法及び細胞培養基盤
JP2022062448A Active JP7516452B2 (ja) 2014-03-04 2022-04-04 改善された再プログラム方法及び細胞培養基盤
JP2023118423A Active JP7738035B2 (ja) 2014-03-04 2023-07-20 改善された再プログラム方法及び細胞培養基盤
JP2025080312A Pending JP2025114793A (ja) 2014-03-04 2025-05-13 改善された再プログラム方法及び細胞培養基盤

Country Status (11)

Country Link
US (1) US11268069B2 (https=)
EP (4) EP3604499A1 (https=)
JP (7) JP6722108B2 (https=)
KR (4) KR102460549B1 (https=)
CN (3) CN120536340A (https=)
AU (3) AU2015227184B2 (https=)
CA (1) CA2941004A1 (https=)
ES (2) ES3050608T3 (https=)
PT (1) PT3114214T (https=)
SG (2) SG10201807292YA (https=)
WO (1) WO2015134652A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655601A4 (en) 2010-12-22 2014-09-10 Fate Therapeutics Inc CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
CA2941004A1 (en) * 2014-03-04 2015-09-11 Peter Flynn Improved reprogramming methods and cell culture platforms
US10023879B2 (en) * 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
CN117737124A (zh) * 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
SG11201803061UA (en) 2015-10-21 2018-05-30 Univ Indiana Res & Tech Corp Methods of generating human inner ear sensory epithelia and sensory neurons
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
SG11201803145RA (en) 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
WO2017123789A1 (en) * 2016-01-12 2017-07-20 Lonza Walkersville, Inc. Methods and vectors to produce vector free induced pluripotent stem cells
KR102537361B1 (ko) * 2016-12-27 2023-05-26 스미또모 가가꾸 가부시키가이샤 인공 다능성 줄기 세포의 평가 방법 및 선발 방법, 그리고 인공 다능성 줄기 세포의 제조 방법
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
JP7554670B2 (ja) 2017-10-11 2024-09-20 フェイト セラピューティクス,インコーポレイテッド 一時的かつ一過性プラスミドベクター発現システムを用いる細胞のリプログラミング
IL316257A (en) 2017-12-22 2024-12-01 Fate Therapeutics Inc Enhanced immune effector cells and use thereof
EP3732286A4 (en) * 2017-12-28 2022-01-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone GENERATION OF INDUCED PLURIPOTENT CELLS BY CRISPR ACTIVATION
EP3768827A1 (en) * 2018-03-22 2021-01-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for reprogramming somatic cells
IL281470B2 (en) 2018-09-28 2025-08-01 Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
MX2021006194A (es) 2018-12-02 2021-06-30 Fate Therapeutics Inc Inmunoterapias mediante el uso de celulas efectoras potenciadas derivadas de ipsc.
CN109679918A (zh) * 2018-12-25 2019-04-26 合肥中科干细胞再生医学有限公司 一种便捷的人诱导性多能干细胞的制备方法
CN113646424A (zh) * 2019-03-29 2021-11-12 富士胶片株式会社 具有分化成特定细胞的能力的多能干细胞的制造方法及其应用
CN110564673A (zh) * 2019-09-26 2019-12-13 广东工业大学 一种干细胞培养液及其应用
KR20220113349A (ko) * 2019-12-11 2022-08-12 리페아론 게엠베하 생물반응기의 현탁액에서 줄기세포의 확장
BR112022025806A2 (pt) 2020-06-19 2023-03-07 Fate Therapeutics Inc Combinação de tipos de células efetoras derivadas de ipsc para uso em imunoterapia
JP2023531963A (ja) * 2020-06-22 2023-07-26 ライフ テクノロジーズ コーポレーション 多能性細胞懸濁物を培養するための方法及び組成物
AU2021353586A1 (en) * 2020-10-02 2023-05-11 Fate Therapeutics, Inc. Improved reprogramming, maintenance and preservation for induced pluripotent stem cells
WO2023192876A1 (en) * 2022-03-28 2023-10-05 Reilly Steve E Composition to increase cellular longevity
US20250222029A1 (en) 2022-04-08 2025-07-10 Fate Therapeutics, Inc. Chimeric antigen receptor for tumor targeting
US20250228943A1 (en) 2022-04-08 2025-07-17 Fate Therapeutics, Inc. Cells having solid tumor targeting backbone and use thereof
CN120283041A (zh) * 2022-10-12 2025-07-08 北京大学 化学重编程的方法和多能干细胞
WO2025152036A1 (en) * 2024-01-16 2025-07-24 Chiou Guang Yuh System and method for increasing the transduction capability and reprogramming efficiency in targeting cells and tissues
WO2025208002A1 (en) * 2024-03-28 2025-10-02 Altos Labs, Inc. Targeted expression of regeneration factors in aged/senescent cells
CN118979011A (zh) * 2024-10-22 2024-11-19 杭州瑞普晨创科技有限公司 人多能干细胞单细胞的建系方法

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
KR0133372B1 (ko) 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
JPH09500534A (ja) 1993-07-22 1997-01-21 メルク エンド カンパニー インコーポレーテッド トランスジェニック動物でのヒトインターロイキン―1βの発現
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US6030943A (en) 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
AU749465B2 (en) 1997-06-13 2002-06-27 Japanese Foundation For Cancer Research Smad6 and uses thereof
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
JP2002521025A (ja) 1998-07-24 2002-07-16 ザ カーネギー インスチチューション オブ ワシントン 増殖因子のTGF−βファミリーのメンバーを使用する、生殖系列幹細胞の維持および増殖のための方法。
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
EP1140062B1 (en) 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
WO2000078351A1 (en) 1999-06-18 2000-12-28 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001017562A1 (fr) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Agents promoteurs de l'osteogenese
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
JP3811775B2 (ja) 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 4−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
EP1437403A4 (en) 2001-09-21 2004-10-27 Japan Science & Tech Corp METHOD FOR PATTERNING REPROGRAMMING FACTOR, METHOD OF PATTERNED REPROGRAMMING FACTOR, METHOD FOR USE OF REPROGRAMMING FACTOR, METHOD FOR DIFFERENTIATING AND SIFE-INGENATING FAN
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Rho−キナーゼ阻害剤
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체
AU2003220935A1 (en) 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
MXPA05003431A (es) 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
AU2004278634B2 (en) 2003-10-03 2009-10-01 Keiichi Fukuda Method of inducing the differentiation of stem cells into cardiomyocytes
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
KR20070030164A (ko) 2003-10-16 2007-03-15 더 유니버시티 코트, 더 유니버시티 오브 에딘버러 Es 세포 자가 재생 및 계통 지정의 조절, 및 이를 위한배지
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
US20080275062A1 (en) 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
JP2008501640A (ja) 2004-04-21 2008-01-24 ザ ユニヴァーシティー オヴ シカゴ ミオシン軽鎖キナーゼ阻害剤及びその使用
US8187878B2 (en) 2004-08-13 2012-05-29 University Of Georgia Research Foundation, Inc. Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors
WO2006026473A2 (en) 2004-08-25 2006-03-09 University Of Georgia Research Foundation, Inc. METHODS AND COMPOSITIONS UTILIZING MYC AND GSK3ß TO MANIPULATE THE PLURIPOTENCY OF EMBRYONIC STEM CELLS
WO2006088867A2 (en) 2005-02-15 2006-08-24 Medistem Laboratories, Incorporated Method for expansion of stem cells
ES2405785T3 (es) 2005-05-18 2013-06-03 Array Biopharma Inc. Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CA2617611A1 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
WO2007030693A2 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
JP5680850B2 (ja) 2006-03-30 2015-03-04 ザ・ユニバーシティ・コート・オブ・ザ・ユニバーシティ・オブ・エディンバラThe University Court of the University of Edinburgh キナーゼインヒビターを含む培養培地およびその使用
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
SE534150C2 (sv) 2006-05-02 2011-05-10 Wisconsin Alumni Res Found Förfarande för differentiering av stamceller till celler av den endodermala och pankreatiska utvecklingslinjen
BRPI0713119A2 (pt) 2006-06-30 2012-04-17 Schering Corp piperidinas substituìdas que aumentam a atividade de p53 e os usos destas
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
ZA200901914B (en) 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
WO2008088882A2 (en) 2007-01-19 2008-07-24 The J. David Gladstone Institutes Methods of generating cardiomyocytes
CA2676044C (en) 2007-01-30 2019-10-22 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
US8158415B2 (en) 2007-02-27 2012-04-17 Procell Therapeutics Inc. Combined use of cell permeable Nanog and Oct4 for increasing self-renewal and suppressing differentiation of stem cells
EP3449923A1 (en) 2007-03-07 2019-03-06 MEI Pharma, Inc. Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
EP2147094B2 (en) 2007-04-18 2018-02-21 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009006422A1 (en) 2007-06-29 2009-01-08 Stem Cell Products, Inc. Automated method and apparatus for embryonic stem cell culture
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
ES2799897T3 (es) 2007-08-31 2020-12-22 Whitehead Inst Biomedical Res Estimulación de la vía wnt en la reprogramación de células somáticas
KR101564044B1 (ko) 2007-10-31 2015-10-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 핵초기화 방법
WO2009061442A1 (en) 2007-11-06 2009-05-14 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells form non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
WO2009073523A2 (en) 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
US20110190729A1 (en) 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
EP2224940A1 (en) 2007-11-30 2010-09-08 Cytomatrix PTY LTD Methods of inducing pluripotency involving oct4 protein
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
WO2009115295A1 (en) 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
EP2307539B1 (en) * 2008-07-30 2014-11-19 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
JP5390624B2 (ja) 2008-11-04 2014-01-15 バイアサイト インク 幹細胞集合体懸濁液組成物、その分化方法
EP3623374B1 (en) 2008-12-03 2021-09-08 The Scripps Research Institute Stem cell cultures
WO2010077955A1 (en) 2008-12-17 2010-07-08 The Scripps Research Institute Generation and maintenance of stem cells
CN101792776B (zh) * 2009-02-01 2013-12-11 中国人民解放军第二军医大学东方肝胆外科医院 一种高效诱导多能性干细胞的重组腺病毒载体、使用该载体的诱导方法及其用途
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
CN102395672A (zh) 2009-04-13 2012-03-28 加利福尼亚大学董事会 用于干细胞培养的方法和组合物
WO2010138750A2 (en) 2009-05-27 2010-12-02 The Salk Institute For Biological Studies Generation of genetically corrected disease-free induced pluripotent stem cells
EP2438159B1 (en) 2009-05-29 2018-10-03 Kyoto University Method for selecting clone of induced pluripotent stem cells
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
WO2010141801A2 (en) * 2009-06-05 2010-12-09 Cellular Dynamics International, Inc. Reprogramming t cells and hematophietic cells
CA2770412C (en) 2009-08-07 2018-09-11 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CA2777720C (en) 2009-10-16 2020-10-06 The Scripps Research Institute Induction of pluripotent cells
KR101874463B1 (ko) 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
WO2011056971A2 (en) 2009-11-04 2011-05-12 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US9005967B2 (en) * 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
CA2789774C (en) 2010-02-17 2024-01-23 Biotime Inc. Methods for telomere length and genomic dna quality control analysis in pluripotent stem cells
EP2542669B1 (en) 2010-03-05 2015-01-21 Texas Heart Institute Ets2 and mesp1 generate cardiac progenitors from fibroblasts
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
WO2011159684A2 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
JPWO2011158852A1 (ja) 2010-06-15 2013-08-19 国立大学法人 東京大学 誘導型多能性幹細胞の製造方法
CA2806858C (en) 2010-08-04 2021-06-15 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
AU2011325439B2 (en) * 2010-11-02 2015-07-23 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Methods and vectors for cell immortalisation
EP2655601A4 (en) * 2010-12-22 2014-09-10 Fate Therapeutics Inc CELL CULTURAL PLATFORM FOR INDIVIDUAL CELL SIZING AND IMPROVED RESOLUTION OF IPSCS
WO2013070852A2 (en) * 2011-11-08 2013-05-16 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
EP2788476B1 (en) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
JP6164746B2 (ja) 2012-05-22 2017-07-19 国立大学法人 東京大学 抗原特異的t細胞の製造方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
CA2941004A1 (en) 2014-03-04 2015-09-11 Peter Flynn Improved reprogramming methods and cell culture platforms
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작

Similar Documents

Publication Publication Date Title
JP2017506904A5 (https=)
JP7738035B2 (ja) 改善された再プログラム方法及び細胞培養基盤
Theunissen et al. Molecular control of induced pluripotency
US12351831B2 (en) Platform for the induction and maintenance of ground state pluripotency
US10954529B2 (en) Minimal volume reprogramming of mononuclear cells
JP7591219B2 (ja) 誘導多能性幹細胞の製造方法及びキット
Gillich et al. Switching stem cell state through programmed germ cell reprogramming
US12618049B2 (en) Reprogramming methods and cell culture platforms
HK40104817A (zh) 用於诱导和维护基态多能性的平台
HK40051615B (en) Improved reprogramming methods and cell culture platforms
HK40051615A (en) Improved reprogramming methods and cell culture platforms
HK40012687A (en) Improved reprogramming methods and cell culture platforms